Loading...
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).
Bader, P Kuçi, Z Bakhtiar, S Basu, O Bug, G Dennis, Michael Greil, J Barta, A Kállay, K Lang, P
Bader, P
Kuçi, Z
Bakhtiar, S
Basu, O
Bug, G
Dennis, Michael
Greil, J
Barta, A
Kállay, K
Lang, P
Citations
Altmetric:
Abstract
The inability to generate mesenchymal stromal cells (MSCs) of consistent potency likely is responsible for inconsistent clinical outcomes of patients with aGvHD receiving MSC products. We developed a novel MSC manufacturing protocol characterized by high in vitro potency and near-identity of individual doses, referred to as "MSC-Frankfurt am Main (MSC-FFM)". Herein, we report outcomes of the 69 patients who have received MSC-FFM. These were 51 children and 18 adults with refractory aGvHD grade II (4%), III (36%) or IV (59%). Patients were refractory either to frontline therapy (steroids) (29%) or to steroids and 1-5 additional lines of immunosuppressants (71%) were given infusions in four weekly intervals. The day 28 overall response rate was 83%; at the last follow-up, 61% and 25% of patients were in complete or partial remission. The median follow-up was 8.1 months. Six-month estimate for cumulative incidence of non-relapse mortality was 27% (range, 16-38); leukemia relapse mortality was 2% (range, 0-5). This was associated with a superior six-month overall survival (OS) probability rate of 71% (range, 61-83), compared to the outcome of patients not treated with MSC-FFM. This novel product was effective in children and adults, suggesting that MSC-FFM represents a promising therapy for steroid refractory aGvHD.
Authors
Bader, P
Kuçi, Z
Bakhtiar, S
Basu, O
Bug, G
Dennis, Michael
Greil, J
Barta, A
Kállay, K
Lang, P
Lucchini, G
Pol, R
Schulz, A
Sykora, K
von Luettichau, I
Herter-Sprie, G
Uddin, M
Jenkin, P
Alsultan, A
Buechner, J
Stein, J
Kelemen, A
Jarisch, A
Soerensen, J
Salzmann-Manrique, E
Hutter, M
Schäfer, R
Seifried, E
Klingebiel, T
Bonig, H
Kuçi, S
Kuçi, Z
Bakhtiar, S
Basu, O
Bug, G
Dennis, Michael
Greil, J
Barta, A
Kállay, K
Lang, P
Lucchini, G
Pol, R
Schulz, A
Sykora, K
von Luettichau, I
Herter-Sprie, G
Uddin, M
Jenkin, P
Alsultan, A
Buechner, J
Stein, J
Kelemen, A
Jarisch, A
Soerensen, J
Salzmann-Manrique, E
Hutter, M
Schäfer, R
Seifried, E
Klingebiel, T
Bonig, H
Kuçi, S
Description
Date
2018-01-29
Publisher
Collections
Files
Keywords
Type
Article
Citation
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). 2018, Bone Marrow Transplant